Sparsentan in APOL1-Mediated Kidney Disease: A DUPLEX Post Hoc Signal and Trial Roadmap (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #FR-PO0646; Pres time: Oct 23, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "While inaxaplin offers a targeted APOL1 approach, complementary downstream strategies remain limited...In the phase 3 DUPLEX trial, sparsentan showed sustained proteinuria reduction versus irbesartan, earning April 2026 FDA approval for FSGS...Conclusion The DUPLEX post-hoc signal, though limited, supports formal evaluation of sparsentan through an APOL1-stratified trial to define its role in dual pathway blockade. Beyond therapeutics, this framework illustrates the importance of genotype-stratified design in addressing trial representation gaps."
Retrospective data • Chronic Kidney Disease • Fibrosis • Focal Segmental Glomerulosclerosis • Glomerulonephritis • Immunology • Inflammation • Nephrology • Renal Disease • EDN1
|
|
Eseosa Omosivie Urhoghide; Merfilius Leslie; Chedis Joseph; Chetna N. Hirani; Sorie P. Kargbo; Amitha Kakulavaram
|